HC Wainwright reiterated their buy rating on shares of Bausch Health Companies (NYSE:BHC) in a report issued on Monday morning, BenzingaRatingsTable reports. HC Wainwright currently has a $60.00 target price on the stock, up from their prior target price of $54.00.
BHC has been the subject of a number of other reports. Zacks Investment Research raised Bausch Health Companies from a hold rating to a buy rating and set a $28.00 price target for the company in a report on Wednesday, November 6th. Wells Fargo & Co reissued a sell rating on shares of Bausch Health Companies in a report on Tuesday, September 17th. Goldman Sachs Group started coverage on shares of Bausch Health Companies in a research report on Monday. They issued a neutral rating and a $30.00 price objective for the company. Guggenheim assumed coverage on shares of Bausch Health Companies in a research report on Thursday, September 12th. They issued a buy rating and a $30.00 price objective for the company. Finally, TD Securities raised shares of Bausch Health Companies from a hold rating to a buy rating and set a $28.00 target price for the company in a research note on Thursday, August 15th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company’s stock. Bausch Health Companies has a consensus rating of Buy and an average price target of $30.74.
Bausch Health Companies stock traded up $0.14 on Monday, reaching $29.10. The company’s stock had a trading volume of 3,227,273 shares, compared to its average volume of 3,815,138. The business’s fifty day moving average price is $26.12 and its 200 day moving average price is $23.44. The company has a debt-to-equity ratio of 9.17, a quick ratio of 0.86 and a current ratio of 1.15. The company has a market cap of $10.20 billion, a price-to-earnings ratio of 7.24 and a beta of 0.90. Bausch Health Companies has a twelve month low of $17.20 and a twelve month high of $29.03.
A number of institutional investors have recently added to or reduced their stakes in the business. Citizens Financial Group Inc RI bought a new position in shares of Bausch Health Companies in the 2nd quarter valued at about $28,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Bausch Health Companies during the 2nd quarter worth approximately $58,000. Captrust Financial Advisors raised its stake in shares of Bausch Health Companies by 41.8% during the second quarter. Captrust Financial Advisors now owns 2,835 shares of the company’s stock worth $71,000 after buying an additional 835 shares during the last quarter. Stonebridge Capital Advisors LLC bought a new stake in shares of Bausch Health Companies during the second quarter worth approximately $171,000. Finally, Lehman & Derafelo Financial Resources LLC acquired a new position in Bausch Health Companies in the second quarter valued at approximately $202,000. Institutional investors own 57.64% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.